Communication Engineering Probiotic Escherichia coli Nissle 1917 for 2′-Fucosyllactose and 3-Fucosyllactose Biosynthesis

Abstract

Fucosylated human milk oligosaccharides are valuable targets for microbial biomanufacturing. Here we engineered the probiotic Escherichia coli Nissle 1917 as a versatile chassis for synthesizing both 2′-fucosyllactose and 3-fucosyllactose. We implemented lactose preservation and blocked colanic acid precursor consumption while reinforcing the de novo GDP-L-fucose pathway. This core module was coupled with either WbgL or FutM2 to drive terminal fucosylation. Initial screening yielded a 2′-fucosyllactose titer of approximately 1.21 g/L. Integrating an additional chromosomal wbgL cassette increased the titer to approximately 1.58 g/L, whereas subsequent genomic modifications did not further improve the 2′-FL titer. Cultivation with 30 g/L glycerol and 5 g/L yeast extract significantly improved productivity, enabling the strain to produce approximately 7.71 g/L of 2′-fucosyllactose in shake-flask cultures. Conversely, the FutM2 strain produced 0.38 g/L 3-fucosyllactose without yeast extract and nutrient supplementation unexpectedly suppressed product accumulation despite promoting biomass formation. The work provides a probiotic-chassis proof of concept and identifies product-module physiology as a priority for further engineering.

Keywords

Nissle 1917 / 2′-Fucosyllactose / 3-Fucosyllactose / GDP-L-fucose / Probiotic chassis

References

[1] Ballard O, Morrow AL . Human milk composition. Pediatr. Clin. N. Am. 2013, 60, 49-74. DOI: 10.1016/j.pcl.2012.10.002

[2] Bode L. The functional biology of human milk oligosaccharides. Early Hum. Dev. 2015, 91, 619-622. DOI: 10.1016/j.earlhumdev.2015.09.001

[3] Goehring KC, Marriage BJ, Oliver JS, Wilder JA, Barrett EG, Buck RH . Similar to those who are breastfed, infants fed a formula containing 2′-fucosyllactose have lower inflammatory cytokines in a randomized controlled trial. J. Nutr. 2016, 146, 2559-2566. DOI: 10.3945/jn.116.236919

[4] Huang D, Yang K, Liu J, Xu Y, Wang Y, Wang R, et al. Metabolic engineering of Escherichia coli for the production of 2′-fucosyllactose and 3-fucosyllactose through modular pathway enhancement . Metab. Eng. 2017, 41, 23-38. DOI: 10.1016/j.ymben.2017.03.001

[5] Barnum CR, Paviani B, Couture G, Masarweh C, Chen Y, Huang YP, et al. Engineered plants provide a photosynthetic platform for the production of diverse human milk oligosaccharides. Nat. Food 2024, 5, 480-490. DOI: 10.1038/s43016-024-00996-x

[6] Lee YG, Jo HY, Lee DH, Yoon JW, Song YH, Kweon DH, et al. De novo biosynthesis of 2ʹ-fucosyllactose by bioengineeredCorynebacterium glutamicum . Biotechnol. J. 2024, 19, 2300461. DOI: 10.1002/biot.202300461

[7] Zhang Q, Xu X, Zhang W, Huang Z, Wu Y, Liu Y, et al. De novo 2′-fucosyllactose biosynthesis using glucose as the sole carbon source by multiple engineered Bacillus subtilis . Metab. Eng. 2025, 88, 85-93. DOI: 10.1016/j.ymben.2024.12.004

[8] Wang H, Zhang H, Zhang Z, Chen X, Lai X . Advances in the biosynthesis and application of sialyllactose. Synth. Biol. Eng. 2025, 3, 10019. DOI: 10.70322/sbe.2025.10019

[9] Chin YW, Kim JY, Lee WH, Seo JH. Enhanced production of 2′-fucosyllactose in engineered Escherichia coli BL21star(DE3) by modulation of lactose metabolism and fucosyltransferase. J. Biotechnol. 2015, 210, 107-115. DOI: 10.1016/j.jbiotec.2015.06.431

[10] Li W, Zhu Y, Wan L, Guang C, Mu W . Pathway optimization of 2′-fucosyllactose production in engineered Escherichia coli . J. Agric. Food Chem. 2021, 69, 1567-1577. DOI: 10.1021/acs.jafc.0c07224

[11] Lin L, Gong M, Liu Y, Li J, Lv X, Du G, et al. Combinatorial metabolic engineering of Escherichia coli for de novo production of 2′-fucosyllactose . Bioresour. Technol. 2022, 351, 126949. DOI: 10.1016/j.biortech.2022.126949

[12] Liu Y, Zhu Y, Wan L, Chen R, Zhang W, Mu W . High-level de novo biosynthesis of 2′-fucosyllactose by metabolically engineered Escherichia coli . J. Agric. Food Chem. 2022, 70, 9017-9025. DOI: 10.1021/acs.jafc.2c02484

[13] Chen Y, Zhu Y, Wang H, Chen R, Liu Y, Zhang W, et al. De novo biosynthesis of 2′-fucosyllactose in a metabolically engineered Escherichia coli using a novel ɑ1,2-fucosyltransferase from Azospirillum lipoferum . Bioresour. Technol. 2023, 374, 128818. DOI: 10.1016/j.biortech.2023.128818

[14] Chen R, Zhu Y, Wang H, Liu Y, Meng J, Chen Y, et al. Engineering Escherichia coli MG1655 for highly efficient biosynthesis of 2′-fucosyllactose by de novo GDP-fucose pathway. J. Agric. Food Chem. 2023, 71, 14678-14686. DOI: 10.1021/acs.jafc.3c05052

[15] Liang S, He Z, Liu D, Yang S, Yan Q, Jiang Z . Construction of an engineered Escherichia coli for effective synthesis of 2′-fucosyllactose via the salvage pathway . Synth. Syst. Biotechnol. 2024, 9, 108-114. DOI: 10.1016/j.synbio.2024.01.001

[16] Li M, Li C, Luo Y, Hu M, Liu Z, Zhang T . Multi-level metabolic engineering of Escherichia coli for high-titer biosynthesis of 2′-fucosyllactose and 3-fucosyllactose . Microb. Biotechnol. 2022, 15, 2970-2981. DOI: 10.1111/1751-7915.14152

[17] Chen G, Wu H, Zhu Y, Wan L, Zhang W, Mu W . Glycosyltransferase from Bacteroides gallinaceum is a novel α-1,3-fucosyltransferase that can be used for 3-fucosyllactose production in vivo by metabolically engineered Escherichia coli . J. Agric. Food Chem. 2022, 70, 1934-1942. DOI: 10.1021/acs.jafc.1c06719

[18] Yu J, Shin J, Park M, Seydametova E, Jung SM, Seo JH, et al. Engineering of α-1,3-fucosyltransferases for production of 3-fucosyllactose in Escherichia coli . Metab. Eng. 2018, 48, 269-278. DOI: 10.1016/j.ymben.2018.05.021

[19] Chen Y, Zhu Y, Wang H, Chen R, Du Z, Mu W . Efficient production of 3-fucosyllactose in a plasmid-free engineered Escherichia coli through strengthening of the GDP-fucose pathway . Food Biosci. 2024, 59, 104154. DOI: 10.1016/j.fbio.2024.104154

[20] Jia R, Li M, Miao M, Zhang T . Efficient de novo synthesis of 3-fucosyllactose in Escherichia coli via enzyme engineering and pathway refinement . Bioresour. Technol. 2025, 436, 132974. DOI: 10.1016/j.biortech.2025.132974

[21] Li N, Yan S, Xia H, Fang Y, Niu K, Li G, et al. Metabolic engineering of Escherichia coli BL21(DE3) for 2′-fucosyllactose synthesis in a higher productivity . ACS Synth. Biol. 2025, 14, 441-452. DOI: 10.1021/acssynbio.4c00598

[22] Zhang K, Gao M, Cao C, Zhang M, Ahmad W, Rady A, et al. Intensification of 2′-Fucosyllactose biosynthesis pathway by using a novel fucosyltransferase from Bacillus cereus. Front. Bioeng. Biotechnol. 2025, 13, 1569597. DOI: 10.3389/fbioe.2025.1569597

[23] Zhu Y, Zhao M, Wang H, Zhu Y, Mu W . Metabolic engineering of Escherichia coli BL21(DE3) cocultured with glucose and xylose for efficient production of 2′-fucosyllactose . Bioresour. Technol. 2025, 419, 132062. DOI: 10.1016/j.biortech.2025.132062

[24] Sonnenborn U. Escherichia coli strain Nissle 1917-from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties . FEMS Microbiol. Lett. 2016, 363, fnw212. DOI: 10.1093/femsle/fnw212

[25] Cress BF, Linhardt RJ, Koffas MAG . Draft genome sequence of Escherichia coli strain Nissle 1917 (serovar O6:K5:H1) . Genome Announc. 2013, 1, e00047-13. DOI: 10.1128/genomeA.00047-13

[26] Revelles O, Millard P, Nougayrède JP, Dobrindt U, Oswald E, Létisse F, et al. The carbon storage regulator (Csr) system exerts a nutrient-specific control over central metabolism in Escherichia coli strain Nissle 1917 . PLoS ONE 2013, 8, e66386. DOI: 10.1371/journal.pone.0066386

[27] Riglar DT, Giessen TW, Baym M, Kerns SJ, Niederhuber MJ, Bronson RT, et al. Engineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation. Nat. Biotechnol. 2017, 35, 653-658. DOI: 10.1038/nbt.3879

[28] Isabella VM, Ha BN, Castillo MJ, Lubkowicz DJ, Rowe SE, Millet YA, et al. Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat. Biotechnol. 2018, 36, 857-864. DOI: 10.1038/nbt.4222

[29] Yu X, Guo J, Sun J, Zhang C . Navigable genome engineering: Stepwise correlation for precision-guided optimization of microbial cell factory phenotypes. Synth. Biol. Eng. 2025, 3, 10003. DOI: 10.70322/sbe.2025.10003

[30] Gan M, Chen C . Synthetic biology-inspired biocontainment strategies of therapeutic genetically engineered bacteria. Synth. Biol. Eng. 2026, 4, 10001. DOI: 10.70322/sbe.2026.10001

[31] Shao F, Wu R, Li ZJ . Metabolic engineering of Escherichia coli Nissle 1917 for the production of heparosan using mixed carbon sources . Fermentation 2025, 11, 289. DOI: 10.3390/fermentation11050289

[32] Fu XZ, Tan D, Aibaidula G, Wu Q, Chen JC, Chen GQ . Development of Halomonas TD01 as a host for open production of chemicals . Metab. Eng. 2014, 23, 78-91. DOI: 10.1016/j.ymben.2014.02.006

[33] Wang MR, Tao S, Lin N, Song X, Li ZJ . Development of Photobacterium sp. LN01 as a versatile halophilic platform for tunable biosynthesis of polyhydroxyalkanoates . ACS Synth. Biol. 2025, 14, 4090-4099. DOI: 10.1021/acssynbio.5c00562